Pupm&Dump trading strategy idea.
$AVXL is rising too much today.
The demand for shares of the company looks lower than the supply.
This and other conditions can cause a fall in the share price today.
So I opened a short position from $23,49;
stop-loss — $24,55;
take-profit — $21,37.
Do not view this idea as a recommendation for trading or investing. It is...
It is my first public analysis after having a dozen or so or private and correct analysis. I believe however I need to disclose I am not a financial advisor, however I am a investor in several of AVXL positions and have been studying this stock for a while.
Anyways, in y analysis I came to spot the formation of the first smaller cup, and fibonacci regressions to...
Sympathy play
Anavex stock gained after favorable data from Cassava Sciences in Alzheimer’s! With a rise yesterday, Cassava Sciences extended its gains after announcement of favorable data from an open-label study in Alzheimer’s disease!
The shares have been on a bullish mode for the last several days, reaching an all-time high, on encouraging data for its...
I like this setup. MACD crossing and the last candle tested both the .50 and .38 fibonacci levels . In addition the current price is near the POC line and the RSI is still very much under control.
Targets: $6.50, $7.70
Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company, which engages in the development of different therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound, ANAVEX2-73, is being developed to treat Alzheimer's and Parkinson's disease and central nervous system diseases, including Rett syndrome. The...
The 200 EMA crossover has occurred again! This time we have positive expectations of earnings as well. A good recipe for gains.
Keeping the analysis simple.
Target price: 3.5+
Keeping the analysis simple, AVXL has crossed over its 200 period EMA whenever it has crossed its 200 EMA in the past it has shot up/down in the direction of the crossover.
Anavex Life Sciences is up on almost 50% higher volume in reaction to the results from a study evaluating the gut microbiota of Alzheimer's patients enrolled in its Phase 2a extension study of ANAVEX 2-73.
The analysis showed that patients receiving ANAVEX 2-73, a sigma-1 receptor (S1R) agonist, had high levels of two gut microbiota families that were associated...
